OVAS OvaScience Inc

OvaScience to Host Third Quarter 2016 Financial Results Conference Call

WALTHAM, Mass.--(BUSINESS WIRE)--

OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m. ET on Thursday, November 3, 2016 to discuss third quarter 2016 financial results and provide a general corporate update.

The live call can be accessed by dialing +1-888-424-8151 for U.S. callers and +1-847-585-4422 for international callers five minutes prior to the start of the call and by providing the passcode 8448237. A live webcast of the conference call will be available online from the Investors section of the Company’s website at www.ovascience.com.

A replay of the conference call will be available from 7:00 p.m. ET on Thursday, November 3, 2016 through 11:59 p.m. ET on Thursday, November 10, 2016, and may be accessed by visiting OvaScience’s website or by dialing +1-888-843-7419 for U.S. callers and +1-630-652-3042 for international callers. The replay access code is 8448237.

About OvaScience

OvaScienceSM (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. OvaScience is developing the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the U.S. For more information, please visit www.ovascience.com and www.augmenttreatment.com or follow us on Twitter and Facebook.

EN
27/10/2016

Underlying

OVASOvaScience Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OvaScience Inc

 PRESS RELEASE
Free
OVAS OVASCIENCE INC

OvaScience Reports First Quarter 2018 Financial Results and Provides B...

WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (Nasdaq:OVAS), a company focused on the development of new treatment options for women and couples struggling with infertility, today reported financial results for the first quarter ended March 31, 2018 and provided a business update. OvaScience is completing preclinical studies designed to evaluate its egg precursor (EggPCSM) cell technology platform and inform the future development of OvaPrime. Based on preliminary data from these experiments and those of OvaScience’s academi...

May 3, 2018 1 EN
 PRESS RELEASE
Free
OVAS OVASCIENCE INC

OvaScience Reports Fourth Quarter and Year-End 2017 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ:OVAS), a company focused on the discovery and development of new treatment options for women and families struggling with infertility, today reported financial results and provided a business update for the fourth quarter and year ended December 31, 2017. “We made a concerted effort over the past six months to hone our strategic focus on research and development, and are positioned to make meaningful progress in our OvaPrime and OvaTure programs in 2018,” said Dr. ...

March 15, 2018 1 EN
 PRESS RELEASE
Free
OVAS OVASCIENCE INC

OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM, Inc. (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced the grant of an inducement award to its newly appointed Chief Scientific Officer, James W. Lillie, Ph.D. The award was approved by OvaScience’s Board of Directors on March 6, 2018 as an inducement material to Dr. Lillie entering into employment with the Company, as permitted under Nasdaq Listing Rule 5635(c...

March 12, 2018 1 EN
 PRESS RELEASE
Free
OVAS OVASCIENCE INC

OvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Resul...

WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScience℠ (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced that it will host a conference call at 4:30 p.m. ET on Thursday, March 15, 2018 to discuss fourth quarter and fiscal year 2017 financial results and provide a general corporate update. The conference call may be accessed by dialing +1-888-424-8151 for U.S. callers and +1-847-585-4422 for international cal...

March 8, 2018 1 EN
 PRESS RELEASE
Free
OVAS OVASCIENCE INC

OVASCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors W...

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQ:OVAS) of the January 22, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in OvaScience stock or options in the Company’s Secondary Offering on or about January 8, 2015 (the “Secondary Offering”) and would like to discuss your legal rights, click here: www.faruq...

January 17, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch